Literature DB >> 26643655

Novel approaches to treating Clostridium difficile-associated colitis.

David Padua1, Charalabos Pothoulakis1.   

Abstract

Clostridium difficile is being recognized as a growing threat to many health-care systems. Epidemiology data shows that infection rates are soaring and the disease burden is increasing. Despite the efficacy of standard treatments, it is becoming evident that novel therapeutics will be required to tackle this disease. These new treatments aim to enhance the intestinal microbial barrier, activate the immune system and neutralize the toxins that mediate this disease. Many of these therapies are still in the beginning stages of investigation, however, in the next few years, more clinical data will become available to help implement many of these exciting new therapeutic approaches.

Entities:  

Keywords:  Clostridium difficile; fecal microbial transplant; novel therapeutics; probiotics; vaccine therapy

Mesh:

Substances:

Year:  2015        PMID: 26643655      PMCID: PMC5979265          DOI: 10.1586/17474124.2016.1109444

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  93 in total

1.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

2.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

Review 3.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

4.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

5.  Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.

Authors:  Daniel M Musher; Nancy Logan; Vaibhav Mehendiratta; Nicolas A Melgarejo; Sagar Garud; Richard J Hamill
Journal:  J Antimicrob Chemother       Date:  2007-03-02       Impact factor: 5.790

6.  Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.

Authors:  Hon Wai Koon; Samantha Ho; Tressia C Hing; Michelle Cheng; Xinhua Chen; Yoshi Ichikawa; Ciarán P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

7.  In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Authors:  David W Hecht; Minerva A Galang; Susan P Sambol; James R Osmolski; Stuart Johnson; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

8.  Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005.

Authors:  Marya D Zilberberg; Andrew F Shorr; Marin H Kollef
Journal:  Pediatr Infect Dis J       Date:  2008-12       Impact factor: 2.129

9.  Clostridium difficile toxin expression is inhibited by the novel regulator TcdC.

Authors:  Susana Matamouros; Patrick England; Bruno Dupuy
Journal:  Mol Microbiol       Date:  2007-06       Impact factor: 3.501

Review 10.  Clostridial binary toxins: iota and C2 family portraits.

Authors:  Bradley G Stiles; Darran J Wigelsworth; Michel R Popoff; Holger Barth
Journal:  Front Cell Infect Microbiol       Date:  2011-12-01       Impact factor: 5.293

View more
  5 in total

1.  Intraluminal Administration of Resiniferatoxin Protects against Clostridium difficile Toxin A-Induced Colitis.

Authors:  Steven R Vigna
Journal:  Gastroenterol Res Pract       Date:  2017-04-17       Impact factor: 2.260

Review 2.  Influence of diet on the gut microbiome and implications for human health.

Authors:  Rasnik K Singh; Hsin-Wen Chang; Di Yan; Kristina M Lee; Derya Ucmak; Kirsten Wong; Michael Abrouk; Benjamin Farahnik; Mio Nakamura; Tian Hao Zhu; Tina Bhutani; Wilson Liao
Journal:  J Transl Med       Date:  2017-04-08       Impact factor: 5.531

3.  Structure and Function of Bovine Whey Derived Oligosaccharides Showing Synbiotic Epithelial Barrier Protective Properties.

Authors:  Peter I Duncan; Olli Aitio; Annamari Heiskanen; Ritva Niemelä; Juhani Saarinen; Jari Helin; Nadine Porta; Muriel Fiaux; Denis Moënnoz; Mireille Golliard; Christine Cherbut; Rafael Berrocal; Sean Austin; Norbert Sprenger
Journal:  Nutrients       Date:  2020-07-06       Impact factor: 5.717

Review 4.  Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Authors:  Hamideh Raeisi; Masoumeh Azimirad; Ali Nabavi-Rad; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

5.  In Vitro Bactericidal Effects of Photodynamic Therapy Combined with Four Tetracyclines against Clostridioides difficile KCTC5009 in Planktonic Cultures.

Authors:  Sung Sook Choi; Hui Yeong Oh; Eui Jin Kim; Hae Kyung Lee; Hyung Keun Kim; Hyun Ho Choi; Sang Woo Kim; Hiun Suk Chae
Journal:  Pathogens       Date:  2020-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.